Limited efficacy of topical recombinant feline interferon-omega for treatment of cats with acute upper respiratory viral disease

Ballin, Anne; Schulz, Bianka; Helps, Christopher R; Sauter‐Louis, Carola; Mueller, Ralf S.; Hartmann, Katrin

doi:10.1016/j.tvjl.2014.09.030

Cited by 18 publications

(22 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Unexpectedly, no beneficial effects were observed in these cats. Ballin et al [85] reported a similar finding; they found that compared to a control group treated with a placebo, cats treated with rFeIFN-ω did not exhibit improved clinical signs of acute viral feline upper respiratory tract disease despite having lower FCV copy numbers than cats receiving rFeIFN-ω [85]. More studies are needed to verify that rFeIFN-ω has a therapeutic effect in vivo.…”

Section: Fcv and Fhv-1mentioning

confidence: 85%

Interferon-omega: Current status in clinical applications

Zhao

Shao

et al. 2017

International Immunopharmacology

View full text Add to dashboard Cite

Since 1985, interferon (IFN)-ω, a type I IFN, has been identified in many animals, but not canines and mice. It has been demonstrated to have antiviral, anti-proliferation, and antitumor activities that are similar to those of IFN-α. To date, IFN-ω has been explored as a treatment option for some diseases or viral infections in humans and other animals. Studies have revealed that human IFN-ω displays antitumor activities in some models of human cancer cells and that it can be used to diagnose some diseases. While recombinant feline IFN-ω has been licensed in several countries for treating canine parvovirus, feline leukemia virus, and feline immunodeficiency virus infections, it also exhibits a certain efficacy when used to treat other viral infections or diseases. This review examines the known biological activity of IFN-ω and its clinical applications. We expect that the information provided in this review will stimulate further studies of IFN-ω as a therapeutic agent.

show abstract

Section: Fcv and Fhv-1mentioning

confidence: 85%

Interferon-omega: Current status in clinical applications

Zhao

Shao

et al. 2017

International Immunopharmacology

View full text Add to dashboard Cite

show abstract

“…rFeIFN-ω was the first licensed interferon compound for use in cats for treatment of FIV and FeLV infection [118]. The first study supporting its clinical application was conducted in 2004 and found that cats infected with FeLV or co-infected FIV displayed a significant clinical improvement and a prolonged survival with rFeIFN-ω treatment [73, 116].…”

Section: Current Potential Applications Of Type I Ifn Classesmentioning

confidence: 99%

Type I Interferons: Distinct Biological Activities and Current Applications for Viral Infection

Gong

Zhao

et al. 2018

Cell Physiol Biochem

139

111

View full text Add to dashboard Cite

The interferons (IFNs) are a primary defense against pathogens because of the strong antiviral activities they induce. IFNs can be classified into three groups: type I, type II and type III, according to their genetic, structural, and functional characteristics and their receptors on the cell surface. The type I IFNs are the largest group and include IFN-α, IFN-β, IFN-ε, IFN-ω, IFN-κ, IFN-δ, IFN-τ and IFN-ζ. The use of IFNs for the treatment of viral infectious diseases on their antiviral activity may become an important therapeutic option, for example, IFN-α is well known for the successful treatment of hepatitis B and C virus infections, and interest is increasing in the antiviral efficacy of other novel IFN classes and their potential applications. Therefore, in this review, we summarize the recent progress in the study of the biological activities of all the type I IFN classes and their potential applications in the treatment of infections with immunodeficiency virus, hepatitis viruses, and influenza viruses.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Recombinant feline interferon-ω (rfeIFN-ω) was the first licensed immunomodulator for use in treating viral infections in cats, especially FIV and FeLV infections [17,18,45]. Furthermore, rfeIFN-ω also exhibits therapeutic effects against other feline viral infections, such as FCV, feline parvovirus, and feline herpesvirus-1 [45], as well as viruses that originate in other animals, such as foot-and-mouth disease virus, influenza virus, BVDV, VSV, PRV, and rotavirus [6,12,18]. In this study, our results demonstrated that both rfeIFN-ωa and rfeIFN-ωb had antiviral activity in homologous animal cells (F81 cells, cat) and heterologous animal cells (Vero cells, monkey; MDBK cells, cattle; MDCK cells, dog; PK-15 cells, pig), indicating that rfeIFN-ωa and rfeIFN-ωb have broad cross-species antiviral activity in vitro, similar to previously published findings in MDBK and MDCK cells [12].…”

Section: Discussionmentioning

confidence: 99%

Cloning, Prokaryotic Soluble Expression, and Analysis of Antiviral Activity of Two Novel Feline IFN-ω Proteins

Wang

Han

et al. 2020

Viruses

View full text Add to dashboard Cite

Cats are becoming more popular as household companions and pets, forming close relationships with humans. Although feline viral diseases can pose serious health hazards to pet cats, commercialized preventative vaccines are lacking. Interferons (IFNs), especially type I IFNs (IFN-α, IFN-β, and interferon omega (IFN-ω)), have been explored as effective therapeutic drugs against viral diseases in cats. Nevertheless, there is limited knowledge regarding feline IFN-ω (feIFN-ω), compared to IFN-α and IFN-β. In this study, we cloned the genes encoding feIFN-ωa and feIFN-ωb from cat spleen lymphocytes. Homology and phylogenetic tree analysis revealed that these two genes belonged to new subtypes of feIFN-ω. The recombinant feIFN-ωa and feIFN-ωb proteins were expressed in their soluble forms in Escherichia coli, followed by purification. Both proteins exhibited effective anti-vesicular stomatitis virus (VSV) activity in Vero, F81 (feline kidney cell), Madin-Darby bovine kidney (MDBK), Madin-Darby canine kidney (MDCK), and porcine kidney (PK-15) cells, showing broader cross-species antiviral activity than the INTERCAT IFN antiviral drug. Furthermore, the recombinant feIFN-ωa and feIFN-ωb proteins demonstrated antiviral activity against VSV, feline coronavirus (FCoV), canine parvovirus (CPV), bovine viral diarrhea virus (BVDV), and porcine epidemic diarrhea virus (PEDV), indicating better broad-spectrum antiviral activity than the INTERCAT IFN. The two novel feIFN-ω proteins (feIFN-ωa and feIFN-ωb) described in this study show promising potential to serve as effective therapeutic agents for treating viral infections in pet cats.

show abstract

Limited efficacy of topical recombinant feline interferon-omega for treatment of cats with acute upper respiratory viral disease

Cited by 18 publications

References 34 publications

Interferon-omega: Current status in clinical applications

Interferon-omega: Current status in clinical applications

Type I Interferons: Distinct Biological Activities and Current Applications for Viral Infection

Cloning, Prokaryotic Soluble Expression, and Analysis of Antiviral Activity of Two Novel Feline IFN-ω Proteins

Contact Info

Product

Resources

About